Todd A. Huffman
Gründer bei Padlock Therapeutics, Inc.
Aktive Positionen von Todd A. Huffman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 01.01.2014 | - |
| Gründer | 01.01.2014 | - | |
| The University of Virginia School of Medicine | Corporate Officer/Principal | - | - |
Karriereverlauf von Todd A. Huffman
Ehemalige bekannte Positionen von Todd A. Huffman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
RCT BioVentures
 RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Private-Equity-Analyst | 01.01.2007 | 30.03.2010 |
Ausbildung von Todd A. Huffman
| University of Virginia | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| 2 |
Operativ
| Private Equity Analyst | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sektoral
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
RCT BioVentures
RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Finance |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Todd A. Huffman
- Erfahrung
